Form 10-Q OCULAR THERAPEUTIX, INC For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Clear Street Reiterates Buy Rating on Ocular Therapeutix (OCUL)
August 5, 2025 11:11 AM EDTClear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "OCUL is trading down (-6%, XBI +/- 0%) after reporting 2Q25 earnings. Revenue was roughly in line ($13.5M vs $13.6M) and expenses outpaced expectations ($51.1M vs $43.1M). But we believe the weakness today is caused by the disclosure that the company tapped into its ATM for $97M in... More
Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)
August 5, 2025 11:07 AM EDTRaymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "Tuesday, before market open, Ocular Therapeutix reported 2Q25 financial results. Management hosted a call to discuss recent progress and outlook for the remainder of 2025. The company reported $13.5M in total revenue vs. our estimated $12.0M and diluted EPS of $(0.39) vs. our... More
